Alkermes plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALKS research report →
Companywww.alkermes.com
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells.
- CEO
- Richard F. Pops
- IPO
- 1991
- Employees
- 1,800
- HQ
- Dublin, IE
Price Chart
Valuation
- Market Cap
- $6.16B
- P/E
- 40.24
- P/S
- 3.95
- P/B
- 3.51
- EV/EBITDA
- 26.75
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 86.63%
- Op Margin
- 12.28%
- Net Margin
- 9.78%
- ROE
- 8.82%
- ROIC
- 3.89%
Growth & Income
- Revenue
- $1.48B · -5.25%
- Net Income
- $241.66M · -34.16%
- EPS
- $1.47 · -33.78%
- Op Income
- $253.96M
- FCF YoY
- 18.41%
Performance & Tape
- 52W High
- $39.56
- 52W Low
- $25.17
- 50D MA
- $32.92
- 200D MA
- $30.75
- Beta
- 0.26
- Avg Volume
- 2.42M
Get TickerSpark's AI analysis on ALKS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 4, 26 | Gaffin David Joseph | sell | 2,034 |
| May 1, 26 | Hopkinson Craig C. | other | 5,000 |
| May 1, 26 | Hopkinson Craig C. | sell | 9,000 |
| May 1, 26 | Hopkinson Craig C. | other | 5,000 |
| Apr 11, 26 | Lurker Nancy | other | 3,751 |
| Apr 11, 26 | Lurker Nancy | other | 901 |
| Apr 11, 26 | Lurker Nancy | other | 3,751 |
| Apr 6, 26 | Gaffin David Joseph | sell | 2,034 |
| Apr 1, 26 | Hopkinson Craig C. | other | 5,000 |
| Apr 1, 26 | Hopkinson Craig C. | sell | 9,000 |
Our ALKS Coverage
We haven't published any research on ALKS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ALKS Report →